EUCTR2013-005157-75-IT进行中（未招募）1 期
Carfilzomib and lenalidomide-based treatment for younger and elderly newly diagnosed primary plasma cell leukemia patients - EMN12/HO129 PC
HOVO0 个研究点目标入组 116 人开始时间: 2021年5月27日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 116
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients with diagnosis of symptomatic pPCL (see appendix A)
- •- Measurable disease as defined by the presence of M-protein in serum or urine (serum M-protein > 10 g/l or urine M-protein > 200 mg/24 hours or abnormal FLC ratio with involved free light chain (FLC) > 100 mg/l) or proven plasmacytoma by biopsy)
- •- Age =18 years
- •- WHO-performance status 0-3 (but WHO=3 is allowed only when caused by pPCL and not by co-morbid conditions)
- •- Written informed consent
- •- Patient capable of giving informed consent (patient is legally, physically and mentally capable of giving consent)
- •- All men and women of childbearing potential should use adequate contraception during the study. Sperm could be frozen from men with child wish before start of treatment
- •- Negative pregnancy test at entry (if applicable)
- •- Patient is willing and able to adhere to the requirements of the lenalidomide Pregnancy Prevention Program (PPP)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 61
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 55
排除标准
- •- Any current CNS involvement with disease refractory to intrathecal chemotherapy.
- •- Female patients who are pregnant or breast feeding.
- •- HIV positive patients
- •- Active malignancy other than pPCL requiring treatment, or a malignancy that has been treated with chemotherapy currently affecting bone marrow capacity
- •- Patients with active, uncontrolled infections
- •- Severe neurological or psychiatric disease
- •- Severe cardiac dysfunction (NYHA classification II-IV, see appendix E)
- •- Severe pulmonary dysfunction
- •- Significant hepatic dysfunction (serum bilirubin or transaminases = 3.0
- •times normal level), unless related to pPCL
- •- Patients with GFR < 15 ml/min
- •- Known history of allergy to Capsidol (a cyclodextrin derivative used to solubilize carfilzomib)
- •- Previous chemotherapy or radiotherapy except local radiotherapy in case of local myeloma progression or corticosteroids maximum 7 days
- •for symptom control or stabilization(this includes dexamethasone 40 mg daily) or inthrathecal chemotherapy in case of CNS involvement
- •- Systemic AL amyloidosis
- •- Any psychological, familial, sociological and geographical condition potentially hampering compliance with the study protocol and follow-up schedule
研究者
相似试验
进行中（未招募）
1 期
Carfilzomib and lenalidomide-based treatment for younger and elderly newly diagnosed primary plasma cell leukemia patientsEUCTR2013-005157-75-NLHOVON Foundation61
进行中（未招募）
1 期
Carfilzomib and lenalidomide-based treatment for younger and elderly newly diagnosed primary plasma cell leukemia patientsPrimary plasma cell leukemiaMedDRA version: 20.0Level: LLTClassification code 10035223Term: Plasma cell leukemiaSystem Organ Class: 100000004864EUCTR2013-005157-75-BEHOVON Foundation61
进行中（未招募）
1 期
Carfilzomib and lenalidomide-based treatment for younger and elderly newly diagnosed primary plasma cell leukemia patientsEUCTR2013-005157-75-GBHOVO16
招募中
2 期
Carfilzomib and lenalidomide-based treatment for younger and elderly newly diagnosed primary plasma cell leukemia patients10035227Plasma cell leukemiaNL-OMON50273HOVO24
进行中（未招募）
1 期
Carfilzomib and lenalidomide-based treatment for younger and elderly newly diagnosed primary plasma cell leukemia patientsPrimary plasma cell leukemiaMedDRA version: 20.0Level: LLTClassification code 10035223Term: Plasma cell leukemiaSystem Organ Class: 100000004864EUCTR2013-005157-75-DKHOVON Foundation61